BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Files An 8-K Entry into a Material Definitive Agreement

BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

ITEM 1.01


ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

Effective February 7, 2017, Boston Scientific Corporation (the
Company) entered into (a) a Second Amended and Restated Credit
and Security Agreement (the Second Amended and Restated Credit
Agreement) by and among Boston Scientific Funding LLC (the
Borrower), the Company, as initial Servicer, Wells Fargo Bank,
National Association and Sumitomo Mitsui Banking Corporation, New
York Branch, as Lenders, Wells Fargo Bank, National Association
and SMBC Nikko Securities America, Inc., as Co-Agents, and Wells
Fargo Bank, National Association, as Administrative Agent, to (i)
extend the term of the Amended and Restated Credit Agreement,
dated as of November 7, 2007 (the Credit Agreement), through
February 7, 2019, (ii) increase the aggregate commitments to
$400,000,000, (iii) allow Lenders to extend credit directly or
through conduits, (iv) allow Lenders, at the request of the
Borrower, to extend LIBOR loans bearing interest by reference to
Libor Market Index Rate, and (v) make certain other amendments to
the Credit Agreement as set forth therein, and (b) a Second
Amended and Restated Receivables Sale Agreement (the Second
Amended and Restated Receivables Sale Agreement), by and among
the Company, each of its direct or indirect wholly-owned
subsidiaries that become a seller thereunder and Boston
Scientific Funding LLC, to (i) incorporate the amendments to the
Amended and Restated Receivables Sale Agreement, dated as of
November 7, 2007 to date, and (ii) make other technical
amendments thereto. In connection and concurrently with the
foregoing, the Amended Fee Letter described in the Credit
Agreement was amended and restated to modify certain fees
thereunder.

Certain of the lenders party to the Second Amended and Restated
Credit Agreement perform certain commercial banking, investment
banking and advisory services for the Company from time to time.

The foregoing description of the Second Amended and Restated
Credit Agreement and Second Amended and Restated Receivables Sale
Agreement is qualified in its entirety by reference to the full
text thereof, copies of which are attached as Exhibits 10.1 and
10.2 to this Current Report on Form 8-K and are incorporated
herein by reference.

ITEM 2.03

CREATION OF A DIRECT FINANCIAL OBLIGATION OR AN
OBLIGATION UNDER AN OFF-BALANCE SHEET ARRANGEMENT OF A
REGISTRANT.

The information set forth above under Item 1.01 is hereby
incorporated by reference into this Item 2.03.

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits
Exhibit No.

Description

10.1
Second Amended and Restated Credit and Security
Agreement, dated as of February 7, 2017, by and among
Boston Scientific Funding LLC, Boston Scientific
Corporation, Wells Fargo Bank, National Association and
Sumitomo Mitsui Banking Corporation, New York Branch, as
Lenders, Wells Fargo Bank, National Association and SMBC
Nikko Securities America, Inc., as Co-Agents, and Wells
Fargo Bank, National Association, as Administrative Agent


10.2

Second Amended and Restated Receivables Sale Agreement,
dated as of February 7, 2017, by and among Boston
Scientific Corporation, each of its direct or indirect
wholly-owned subsidiaries that become a seller
thereunder and Boston Scientific Funding LLC


About BOSTON SCIENTIFIC CORPORATION (NYSE:BSX)

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven core businesses: Interventional Cardiology, Peripheral Interventions (PI), Cardiac Rhythm Management (CRM), Electrophysiology (EP), Endoscopy, Urology and Pelvic Health, and Neuromodulation. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and PI businesses. Its Rhythm Management segment consists of CRM and EP businesses. Its MedSurg segment consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its interventional cardiology products include Drug-Eluting Coronary Stent Systems, Core Coronary Technology, Intravascular Imaging and Structural Heart Therapy. Its peripheral products include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters.

BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) Recent Trading Information

BOSTON SCIENTIFIC CORPORATION (NYSE:BSX) closed its last trading session down -0.14 at 25.20 with 6,027,410 shares trading hands.

An ad to help with our costs